Promising combo aims to wipe out hidden cancer cells in triple negative breast cancer
NCT ID NCT04333706
First seen Apr 10, 2026 · Last updated May 15, 2026 · Updated 5 times
Summary
This study tests a combination of two drugs, sarilumab and capecitabine, in people with aggressive breast cancer (triple negative or hormone-resistant). The goal is to eliminate tiny amounts of cancer that remain after standard treatment, which can lead to deadly spread. About 65 adults with advanced or high-risk early-stage breast cancer will participate. The study first finds the safest dose, then checks if the treatment can clear cancer cells from the blood and bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Los Angeles General Medical Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UF Health
ACTIVE_NOT_RECRUITINGGainesville, Florida, 32610, United States
-
USC/Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.